☆ 4.6 Article

Lack of pharmacokinetic interaction between derazantinib and naringin in rats

PHARMACEUTICAL BIOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines

Mario E. Lacouture et al.

Summary: FGFR aberrations in cholangiocarcinoma and bladder cancer led to development of selective FGFR inhibitors for these indications. FGFR inhibitors are associated with a unique class effect of adverse events affecting skin, hair, and nails, with management guidelines aimed at increasing awareness and providing effective treatment strategies to improve quality of life.

ONCOLOGIST (2021)

Add to Collection

Article Pharmacology & Pharmacy

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma

Stephan Braun et al.

Summary: This review evaluates the clinical role of derazantinib, an investigational FGFR inhibitor, in patients with iCCA harboring actionable FGFR2 genetic aberrations. Derazantinib has shown clinically meaningful efficacy with durable objective responses, supporting its therapeutic potential in previously treated iCCA patients. The safety profile of derazantinib was manageable and compared favorably to other FGFR inhibitors, indicating the need for increased molecular profiling of cholangiocarcinoma patients.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article Oncology

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman et al.

Summary: The study utilized genomic profiling data to explore the genomic landscape and molecular diversity of patients with cholangiocarcinoma, as well as analyze the clinicogenomics of patients treated with pemigatinib, highlighting the utility of genomic profiling in clinical trials.

CANCER DISCOVERY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?

Gabriella Aitcheson et al.

Summary: With the increasing availability of next-generation DNA sequencing (NGS), personalized therapy has become possible, particularly in intrahepatic cholangiocarcinoma (iCCA) with actionable genomic targets such as Isocitrate Dehydrogenase (IDH) mutations and Fibroblast Growth Factor Receptor (FGFR) mutations, especially FGFR2. Current data show survival benefit with FGFR2 inhibitors in iCCA patients positive for FGFR2 fusion who have failed standard treatment.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review

Zahra Memariani et al.

Summary: Cancer rates are increasing in many low- and middle-income countries due to various factors, including lifestyle changes and societal problems. Different treatment approaches like chemotherapy, surgery, and radiation therapy are used, but can have various short- and long-term side effects. Recent studies show that compounds like naringin and naringenin from citrus fruits have anti-cancer properties through different signaling pathways, and when combined with current anti-cancer agents, can show synergistic effects and help overcome multidrug resistance in cancer treatment.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Review Oncology

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma

Gentry King et al.

Summary: Cholangiocarcinoma is a challenging cancer to treat, with genetic alterations in FGFR identified in a significant number of patients. Selective FGFR inhibitors have shown promise in treating this population, but resistance is a concern. New compounds, sequencing strategies, and combinations are needed to overcome this resistance and optimize therapeutic outcomes.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Systemic therapies for intrahepatic cholangiocarcinoma

Robin Kate Kelley et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells

Hany Elsawy et al.

BIOSCIENCE REPORTS (2020)

Add to Collection

Article Oncology

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species

Yang Bai et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Article Pathology

Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

Chiara Raggi et al.

AMERICAN JOURNAL OF PATHOLOGY (2019)

Add to Collection

Article Oncology

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

News Item Oncology

Derazantinib for intrahepatic cholangiocarcinoma

Elizabeth Gourd

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Maeve A. Lowery et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype

Apurva Jain et al.

JCO PRECISION ONCOLOGY (2018)

Add to Collection

Article Oncology

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

K. P. Papadopoulos et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-apoptotic and anti-inflammatory effects of naringin on cisplatin-induced renal injury in the rat

Yassine Chtourou et al.

CHEMICO-BIOLOGICAL INTERACTIONS (2016)

Add to Collection

Article Multidisciplinary Sciences

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Terence G. Hall et al.

PLOS ONE (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells

Hung-Rong Yen et al.

CHEMICO-BIOLOGICAL INTERACTIONS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Workshop Report: Crystal City V-Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance

Brian Booth et al.

AAPS JOURNAL (2015)

Add to Collection

Review Gastroenterology & Hepatology

Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma

Sumera Rizvi et al.

GASTROENTEROLOGY (2013)

Add to Collection

Review Food Science & Technology

Mechanisms of Cisplatin Nephrotoxicity

Ronald P. Miller et al.

TOXINS (2010)

Add to Collection

Article Pharmacology & Pharmacy

Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats

Sung-Cil Lim et al.

BIOPHARMACEUTICS & DRUG DISPOSITION (2006)

Add to Collection

Article Urology & Nephrology

Metabolism of cisplatin to a nephrotoxin in proximal tubule cells

DM Townsend et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.